113 studies on Growth factor class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This global registry represents a crucial step in understanding the long-term safety and effectiveness of Increlex® for SPIGFD. By collecting data from a large, diverse patient population over many years, it can ident…
If successful, this research could provide a non-pharmacological strategy to mitigate breast cancer risk in individuals with BRCA mutations. Understanding the impact of diet on biomarkers like IGF-I could empower muta…
The demonstration of safety and feasibility for the Fasting Mimicking Diet (FMD) in cancer patients is a significant step, as it suggests that this non-pharmacological intervention could be safely integrated into exis…
**FecB-carrier ovarian cells require 3–10-fold lower BMP concentrations to mount a maximal steroidogenic response**, meaning even trace paracrine BMP signals are sufficient to drive full differentiation — a mechanisti…
**SphK1-derived S1P is the 'missing link' through which IGFBP-3 amplifies both IGF and EGF receptor signaling**, reframing IGFBP-3 not merely as an IGF carrier but as an active lipid-signaling inducer. For researchers…
This research highlights a critical risk for individuals using anabolic peptides like **IGF-1-LR3** in the context of active cancer. While the peptide effectively preserved muscle mass, its growth-promoting properties…
This research reveals a critical dependency: the anabolic effects of both **estradiol** and **IGF-1 LR3** on muscle stem cells require a functional Epidermal Growth Factor Receptor (`EGFR`). For researchers and biohac…
These findings suggest that **IGF-1 LR3 could be a viable strategy to safely increase both heart muscle and its supporting blood supply before birth**. For potential therapeutic applications aimed at improving congeni…
This research provides a potential mechanistic explanation for the reduced β-cell function seen in overgrown newborns from pregnancies complicated by conditions like diabetes. The finding that elevated IGF-1 can direc…
This study provides evidence that activating the `GHSR` to enhance the body's natural, pulsatile GH release pattern is a viable strategy for managing obesity and its metabolic complications. For individuals exploring …
This Phase 4 study is significant because it investigates a sequential therapy approach for Thyroid Associated Ophthalmopathies (TAO), a debilitating condition often resistant to current treatments. IBI311, as an anti…
Understanding the role of post-exercise protein in bone health could significantly impact recovery protocols for endurance runners and other athletes, potentially reducing the risk of stress fractures and osteoporosis…
This research is critical for understanding the molecular mechanisms behind skin aging and its response to environmental stressors like UVB. If Insulin-Like Growth Factor 1 proves effective in modulating gene expressi…
If GHRH were found to be effective, this research could pave the way for a novel therapeutic strategy to address age-related sleep disturbances, a widespread issue affecting millions. Successfully augmenting the GH-IG…
The intent behind this study highlights a critical challenge in endocrinology: the potential for significant inter-assay variability to compromise the accurate diagnosis and management of Growth Hormone (GH) disorders…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The withdrawal of this study means a significant opportunity was missed to explore a potential therapeutic avenue for muscle wasting in advanced CKD. Sarcopenia in CKD patients is a major predictor of morbidity and mo…
The findings suggest acylated ghrelin could be a powerful therapeutic adjunct for patients undergoing **doxorubicin chemotherapy**, a cornerstone of cancer treatment plagued by cardiotoxic side effects. By directly co…
**Peptide secretagogues do not merely turn up GH output — they fundamentally reshape the kinetics of each burst**, a finding with direct implications for dosing strategy. Clinicians and researchers using combined **GH…
**Clinicians managing TBI or SAH survivors should consider routine GH axis screening**, as hypopituitarism and aGHD are far more prevalent in this population than traditionally assumed. The **GHRP-2 test's <9 ng/mL cu…
**Clinicians and peptide users targeting GH optimization cannot rely on testosterone normalization alone** to restore somatotropic function — AVF and IGF-I levels are independent, dominant modulators. For practitioner…
**GHRP-2's secretagog efficacy is uniquely insensitive to the hormonal and metabolic factors that blunt GHRH-driven GH release**, including visceral adiposity and the IGF-1 / IGFBP axis. For clinicians and researchers…
**Any consumer purchasing this supplement was unknowingly ingesting a WADA-prohibited peptide capable of stimulating the hGH/IGF-1 axis**, with no dosing guidance, safety oversight, or disclosure. For athletes, a posi…
**Finding GHRP-2 in commercially available nutritional supplements** means athletes and consumers may be unknowingly ingesting a non-approved peptide with systemic GH-releasing activity, creating both unintentional do…
The study demonstrates two distinct and effective pharmacological pathways to combat growth retardation caused by somatotropic axis deficiency. For users of growth hormone secretagogues, this provides evidence that **…
For athletes and regulatory bodies, this research provides a pathway to more effective and reliable anti-doping controls for hGH. The identification of `RAB31` and `FN1` as robust biomarkers could lead to new testing …
This research provides a crucial tool for anti-doping agencies to identify the use of black market follistatin. The discovery that all tested genuine products contain His-tags is a game-changer for testing, as it prov…
This research reveals a novel and critical role for the RECK protein in maintaining the stability and proper function of the GH/IGF-1 axis. The observed discordance between receptor protein levels and their mRNA sugge…
The findings position the GHRH analog **MR-409** as a potent mitogenic and anti-apoptotic agent for skin cells, suggesting it could be a valuable tool for enhancing tissue repair. For clinicians and individuals dealin…
**Systemic GH secretagogue use — including MK-0677 — does not elevate CNS IGF-1 or GH levels**, which has direct implications for researchers and clinicians who hypothesize that peripheral GH/IGF-1 elevation might pro…
**Oral MK-677 produced measurable increases in both bone formation and resorption markers**, suggesting coupled bone remodeling rather than isolated catabolism — a more favorable skeletal profile than pure resorption-…
**Clinicians and advanced users should note the transient nature of leptin elevation** — an effect that normalizes by 8 weeks — which suggests early adaptation in the `leptin` signaling axis and argues against long-te…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
**Femoral neck fracture is among the most clinically consequential osteoporotic injuries**, making even a modest site-specific BMD advantage potentially meaningful for fracture prevention — the combination's **+1.7 pe…
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the b…
**The 84% IGF-1 elevation confirms MK-0677 reliably engages its target even in elderly, post-surgical patients** — a pharmacokinetically important signal for clinicians and researchers designing GH-axis interventions.…
**GHS compounds including GHRP-2, GHRP-6, and MK-677 target four converging GH-axis nodes simultaneously**, which explains their superior efficacy over single-mechanism secretagogues and provides a pharmacological rat…
**The type of GHSR agonist chosen determines not just direct receptor activation but also how the body's own ghrelin pulses are amplified or suppressed.** For clinicians and researchers, this means MK-677's pharmacolo…
**Clinicians and researchers** targeting age-related cardiovascular decline now have a cellular mechanism — EPC restoration via `IGF-1` — to anchor therapeutic protocols around GH secretagogues or direct IGF-1 interve…
**Oral MK-677 at 25 mg/day demonstrably attenuates age-related lean mass loss** and restores `IGF-1` to youthful concentrations, establishing proof-of-concept that `GHSR` agonism can counter one measurable dimension o…
**The ago-allosteric model for MK-677 and GHRP-6 is not supported in this assay system** — meaning assumptions about synergistic or supra-additive effects when combining ghrelin-pathway compounds with these secretagog…
**Elevated IGF-1 alone does not translate to clinically meaningful functional recovery** in frail elderly hip fracture patients — a finding that should temper enthusiasm for `GHSR` agonists in this population. The eme…
This study establishes that MK-0677 is effective at raising IGF-1 levels in the specific, vulnerable population of hemodialysis patients, a group where anabolic support is critically needed to combat protein-energy wa…
These findings highlight a significant challenge for the long-term use of oral GHSs like MK-677 for growth promotion. While the compound can acutely stimulate a robust GH pulse, the body appears to develop a powerful …
**AOD9604's lipolytic mechanism is indirect**: it drives `beta(3)-AR` gene expression upward rather than binding the receptor itself, meaning protocols relying on stacking it with `beta3-AR` agonists (e.g., ephedrine-…